HDT Bio announces peer─reviewed article describing the development of an RNA vaccine to prevent infection and disease ...
HDT Bio Corporation, a Seattle-based clinical-stage biopharmaceutical company and developer of immunotherapies for oncology and infectious diseases, has announced the publication demonstrating the potential for self-amplifying RNA vaccines to be used as …